Drug Safety Update - August 2024
The Medicines and Healthcare products Regulatory Agency (MHRA) has published Drug Safety Update for August 2024 (PDF).
This issue advises clinicians about a collaboration between the MHRA and Genomics England that aims to improve understanding of how a patient's genetic makeup may increase their risk of experiencing harmful side effects to medicines. It is hoped that specific genetic traits that predispose patients to serious side effects can be identified; in time this could allow pre-treatment screening and improved medicines safety. This pilot stage will investigate severe bleeding events with DOACs and severe skin reactions with allopurinol. Yellow cards already submitted for such reactions, and any future cards submitted may result in the reporter being contacted to encourage participation in this pilot.
Lastly, this issue contains a summary of letters to healthcare professionals in July. These generally related to supply issues and recalls.
Action: Clinicians should be aware of this month's new guidance and implement any necessary changes to practice.
| « SMC Update - August 2024 | NICE Guidance - August 2024 » |
Leave a Comment